Antegren humanized antibody: ATHN will begin a Phase II trial in the U.K.

The drug is a humanized antibody directed against the alpha-4 beta-1 integrin receptor, which is expressed on white blood cells. ATHN said that blocking white cell migration into the brain has been sh...